

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A pharmaceutical composition formulated for oral, rectal, intravenous, intramuscular, subcutaneous, inhalation, vaginal, or ophthalmic administration, said composition comprising amoxapine and a corticosteroid, wherein the amoxapine and corticosteroid are present in amounts that, when administered together to a patient having an inflammatory disorder, inhibit or reduce inflammation.
2. (Original) The composition of claim 1, wherein amoxapine is present in the composition in an amount of 1-600 milligrams.
3. (Original) The composition of claim 2, wherein amoxapine is present in the composition in an amount of 100-300 milligrams.
4. (Original) The composition of claim 1, wherein the steroid is present in the composition in an amount of 0.05-200 milligrams.
5. (Original) The composition of claim 4, wherein the steroid is present in the composition in an amount of 0.05-5 milligrams.
6. (Original) The composition of claim 5, wherein the steroid is present in the composition in an amount of 0.1-3 milligrams.
7. (Original) The composition of claim 1, wherein the composition is formulated for oral administration.
8. (Currently amended) The composition of claim 1, wherein the composition is formulated for rectal ~~topical~~ administration.